Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 2, 2014, Pages 103-109

  Mahler, Donald A ^a,b   Waterman, Laurie A ^a,b   Ward, Joseph ^a,b   Gifford, Alex H ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Dry powder inhaler; Lung function; Nebulized bronchodilator; Peak inspiratory flow rate

Indexed keywords

ARFORMOTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; SALMETEROL; AEROSOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; POWDER; SALBUTAMOL;

AEROSOL; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; MALE; MEDICAL DEVICE; NEBULIZATION; NEBULIZER; PEAK INSPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPIROMETRY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INHALATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT PREFERENCE; POWDER; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME; UNITED STATES; VERY ELDERLY; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; AGED; AGED, 80 AND OVER; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INHALATION; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NEW HAMPSHIRE; PATIENT PREFERENCE; POWDERS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84897037895     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1038     Document Type: Article

References (30)

1. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, and Chrystyn H: ERS/ISAM task force report: what the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 201137:1308-1331.
2. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, and Chrystyn H: Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007101:2395-2401.
3. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T, Troosters T, and Decramer MJ: Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 200831:78-83.
4. Vincken W, Dekhuijzen PR, and Barnes P ADMIT Group: The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J. 201019:10-20.
5. Sestini P, Cappiello V, Aliani M, Martucci P, Sena A, Vaghi A, Canessa PA, Neri M, and Melani AS: Prescription bias and factors associated with improper use of inhalers. J Aerosol Med. 200619:127-136.
6. Mahler DA, Waterman LA, and Gifford AH: Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013 [Epub ahead of print].
7. Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, and Rinehart M. Nebulized formoterol fumarate: dose selection and pharmacokinetics. Pulm Pharmacol Ther. 200821:818-823.
8. Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, and Hanrahan JP: The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 7:17-31.
9. Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, and Baumgartner RA: Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 20085:25-34.
10. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, and Hanrahan JP: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 200729:261-278.
11. van der Palen J: Peak inspiratory flow through Diskus and Turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respir Med. 200397:285-289.
12. Clark AR, and Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med. 19936:99-110.
13. Celli BR, and MacNee W ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 200423:932-946.
14. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: General considerations for lung function testing. Eur Respir J. 200526:153-161.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: Standardisation of spirometry. Eur Respir J. 200526: 319-338.
16. Hankinson JL, Odencrantz JR, and Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999159:179-187.
17. Crapo RO, Morris AH, Clayton PD, and Nixon CR: Lung volumes in healthy nonsmoking adults. Bull Eur Physiopath Respir. 198218:419-425.
18. Han MK, Wise R, Mumford J, Sciurba F, Criner GJ, Curtis JL, Murray S, Sternberg A, Weinman G, Kazerooni E, Fishman AP, Make B, Hoffman EA, Mosenifar Z, and Martinez FJ: Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J. 201035:1048-1056.
19. O'Donnell DE, Forkert L, and Webb KA: Evaluation of bronchodilator responses in patients with ''irreversiblé' emphysema. Eur Respir J. 200118:914-920.
20. Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, and McDonald JD: Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane- 134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immun. 2012108:195-200.
21. Walker PS, Petterson GL, Bondesson E, and Conway JH: An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder. J Aerosol Med. 200114:227-236.
22. Ramirez-Venegas A, Ward J, Lentine T, and Mahler DA: Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest. 1997112:336-340.
23. Newton MF, O'Donnell DE, and Forkert L: Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002121:1042-1050.
24. Atkins PJ: Dry powder inhalers: an overview. Respir Care. 200550:1304-1312.
25. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Busasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palango P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, and Wouters EF American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 200831:416-469.
26. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, and Lannefors L: European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 200118:228-242.
27. Qaseem A, Wilt TJ, Weinberger SE, Snow V, Hanania NA, Criner G, van der Molen T, Marciniuk D, Denberg T, Schunemann H, Wedzicha W, MacDonald R, and Shekelle P: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011155:179-191.
28. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, and Voduc N: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J. 2007;14 Suppl B:5B-32B.
29. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, and Rodriguez-Roisin R: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med. 2013187:347-365.
30. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, and Baird JC: Validity and responsiveness of the selfadministered computerized versions of the baseline and transition dyspnea indexes. Chest. 2007132:1283-1290.